CN Bio appoints US director of sales as OOC market expands
CN Bio has appointed Joe Parisi as US director of sales to support accelerated growth in what is a key organ-on-a-chip (OOC) market.
Based in Colorado, Joe will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.
The global demand for NAMs has accelerated, particularly in the US following the enactment of the FDA Modernization Act 2.01. Joe’s sales expertise will be backed by support for customers to improve the human relevance of preclinical workflows and reduce animal model reliance.
He has a BSc in Molecular and Cellular Biology from the University of Illinois Urbana-Champaign, and has held senior roles at numerous life sciences organisations including Isoplexis, NanoString Technologies, and Life Technologies. Joe joins CN Bio from Phenomix (acquired by Bruker Corporation in 2023), where he was director of sales for US West and led an experienced sales team.
Joe said: “The potential offered by CN Bio’s PhysioMimix range, substantiated by the company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficiency and minimise drug failures.”
CN Bio CEO Dr Paul Brooks said: “It is great to welcome Joe to the team. Throughout his career, he has repeatedly demonstrated his expertise in biotech sales, with a proven history of success across companies at all stages of growth and commercialisation.
“Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US, a key market for innovative drug discovery.”